BioCryst Pharmaceuticals, Inc. (BCRX)
7.61
-0.07
(-0.91%)
USD |
NASDAQ |
Nov 13, 16:00
7.60
-0.01
(-0.13%)
After-Hours: 19:59
BioCryst Pharmaceuticals Enterprise Value : 2.402B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 2.402B |
| November 12, 2026 | 2.420B |
| November 11, 2026 | 2.412B |
| November 10, 2026 | 2.381B |
| November 09, 2026 | 2.407B |
| November 06, 2026 | 2.422B |
| November 05, 2026 | 2.407B |
| November 04, 2026 | 2.563B |
| November 03, 2026 | 2.648B |
| November 02, 2026 | 2.564B |
| October 30, 2026 | 2.622B |
| October 29, 2026 | 2.635B |
| October 28, 2026 | 2.596B |
| October 27, 2026 | 2.527B |
| October 26, 2026 | 2.471B |
| October 23, 2026 | 2.412B |
| October 22, 2026 | 2.445B |
| October 21, 2026 | 2.438B |
| October 20, 2026 | 2.486B |
| October 19, 2026 | 2.520B |
| October 16, 2026 | 2.448B |
| October 15, 2026 | 2.507B |
| October 14, 2026 | 2.514B |
| October 13, 2026 | 2.520B |
| October 12, 2026 | 2.594B |
| Date | Value |
|---|---|
| October 09, 2026 | 2.642B |
| October 08, 2026 | 2.576B |
| October 07, 2026 | 2.604B |
| October 06, 2026 | 2.489B |
| October 05, 2026 | 2.527B |
| October 02, 2026 | 2.545B |
| October 01, 2026 | 2.532B |
| September 30, 2026 | 2.586B |
| September 29, 2026 | 2.595B |
| September 28, 2026 | 2.646B |
| September 25, 2026 | 2.676B |
| September 24, 2026 | 2.658B |
| September 23, 2026 | 2.671B |
| September 22, 2026 | 2.725B |
| September 21, 2026 | 2.720B |
| September 18, 2026 | 2.699B |
| September 17, 2026 | 2.704B |
| September 16, 2026 | 2.635B |
| September 15, 2026 | 2.567B |
| September 14, 2026 | 2.584B |
| September 11, 2026 | 2.556B |
| September 10, 2026 | 2.600B |
| September 09, 2026 | 2.731B |
| September 08, 2026 | 2.798B |
| September 04, 2026 | 3.026B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics, Inc. | 13.60B |
| Neurocrine Biosciences, Inc. | 16.61B |
| Agenus, Inc. | 487.93M |
| Amgen, Inc. | 292.70B |
| Anika Therapeutics, Inc. | 160.67M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 37.92M |
| Revenue (Quarterly) | 180.29M |
| Total Expenses (Quarterly) | 142.38M |
| EPS Diluted (Quarterly) | 0.1417 |
| Gross Profit Margin (Quarterly) | 98.99% |
| Profit Margin (Quarterly) | 21.03% |
| Earnings Yield | -18.67% |
| Operating Earnings Yield | 21.59% |
| Normalized Earnings Yield | 8.314 |